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guanine-DNA methyltransferase (MGMT) inhibits the





tivity is controlled by a promoter; methylation of the
promoter silences the gene in cancer, and the cells no
longer produce MGMT. We examined gliomas to de-














 promoter in tumor
DNA by a methylation-specific polymerase-chain-reac-
tion assay. The gliomas were obtained from patients
who had been treated with carmustine (1,3-bis(2-chlo-
roethyl)-1-nitrosourea, or BCNU). The molecular data








 promoter was methylated in
gliomas from 19 of 47 patients (40 percent). This find-
ing was associated with regression of the tumor and
prolonged overall and disease-free survival. It was an
independent and stronger prognostic factor than age,









gliomas is a useful predictor of the responsiveness of
the tumors to alkylating agents. (N Engl J Med 2000;
343:1350-4.)
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LKYLATING agents are highly reactive





 The most frequent site of





guanine. Alkylation here forms cross-links between




 which explains how the
nitrosoureas, tetrazines, and procarbazine kill cells.
The cross-linking of double-stranded DNA by alkyl-













transferase. The MGMT protein rapidly reverses alkyl-









the formation of lethal cross-links. Through this mech-




The level of MGMT varies widely according to the
type of tumor, and even varies among tumors of the





 This deficiency of the enzyme









 gene is not com-
monly mutated or deleted, a lack of MGMT may be
caused by changes that do not alter the genetic infor-
mation of the cell. Methylation of DNA is the main





it plays an important part in tumorigenesis. In par-
ticular, methylation of normally unmethylated sites,
known as CpG (cytidine phosphate guanosine) islands,
in the promoter regions of tumor-suppressor and
DNA-repair genes is correlated with loss of expres-









gene prevents transcription of the gene, and in cell













Furthermore, in vitro treatment with demethylating









We performed a study to determine whether meth-





could be used to identify gliomas that were respon-
sive to alkylating drugs.
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Patients and Tumor Specimens
 
We studied specimens of brain tumors from 47 consecutive pa-
tients referred to the University Hospital of Navarre, in Pamplona,
Spain, between April 1993 and November 1998. All the patients
provided written informed consent. All had histologically verified
tumors: 18 had an anaplastic astrocytoma, and 29 had a glioblas-
toma multiforme. Patients were 38 to 70 years old (median age at
diagnosis, 55 years); 30 were men, and 17 were women. Tumor
specimens were obtained by resection or biopsy performed before
the initiation of treatment with radiation and chemotherapy and
were immediately frozen and stored at ¡80°C. All patients were
treated with intraarterial cisplatin (50 mg per square meter of body-
surface area), whole-brain radiotherapy, and a median of three
courses of intravenous carmustine (1,3-bis(2-chloroethyl)-1-nitro-
sourea, or BCNU; 100 mg per square meter) given at four-week
intervals. Fifteen of the patients also underwent autologous bone
marrow transplantation plus high-dose chemotherapy treatment
with three doses of intravenous carmustine (300 mg per square
meter) per day and one dose of intraarterial cisplatin (100 mg).
The response to treatment was evaluated after the patients had
completed therapy. A complete response was defined as the ab-
sence of any evidence of the tumor on computed tomographic (CT)
and magnetic resonance imaging (MRI) scans, with no need for
steroid treatment and an improvement in the patient’s general con-
dition. Patients with persistent CT abnormalities but with more than
a 50 percent reduction in both the diameter and the volume of
the tumor, a reduced need for steroid treatment, and a stabilized
neurologic condition were considered to have a partial response.
The disease was considered to have progressed if both the diam-
eter and volume of the tumor increased by 25 percent or more of
the initial measurements, if a new lesion was evident on CT or MRI
scans, or if the patient’s neurologic condition worsened and re-




DNA was extracted according to standard protocols. Methyla-




 were determined by
chemical modification of unmethylated, but not methylated, cy-
tosines to uracil. Methylation-specific polymerase chain reaction
(PCR) was performed with primers specific for either methylated




















 leading to the loss
of MGMT protein. DNA adducts produced by carmustine in these tumors are not efficiently removed, leading to tumor-cell death




 promoter and exon 1 region express MGMT protein, which
removes guanine adducts from the DNA produced by the administration of carmustine (BCNU), resulting in resistance to the tu-
morocidal and toxic effects drug. 





strands, and there is no activeB
MGMT to repair it Gene inactivation
DNA remains cross-linked,B
and tumor cells die
Glioma with unmethylated MGMT Chemoresistant tumor
Alkyl group removed by B
MGMT from the DNA B
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with sodium bisulfite. DNA samples were then purified with the
Wizard DNA purification resin (Promega, Madison, Wis.), again
treated with sodium hydroxide, precipitated with ethanol, and resus-
pended in water. Primer sequences for the unmethylated reaction
were 5'TTTGTGTTTTGATGTTTGTAGGTTTTTGT3' (forward
primer) and 5'AACTCCACACTCTTCCAAAAACAAAACA3' (re-
verse primer), and for the methylated reaction they were
5'TTTCGACGTTCGTAGGTTTTCGC3' (forward primer) and
5'GCACTCTTCCGAAAACGAAACG3' (reverse primer). The an-




I methyltransferase (New England Biolabs, Beverly, Mass.) was





DNA from normal lymphocytes was used as a negative control.
Controls without DNA were used for each set of methylation-spe-
cific PCR assays. Ten microliters of each 50-µl methylation-specif-
ic PCR product was loaded directly onto nondenaturing 6 percent





Continuous variables were compared with the use of Student’s
t-test. Contingency tables were analyzed by Fisher’s exact test. Dis-
ease-free and overall survival curves were estimated by the Kaplan–
Meier method and were compared with the use of the log-rank
test. Multivariate survival analyses were performed with the Cox
proportional-hazards model, and proportional-hazards assumptions
were checked with the use of Schoenfeld residuals and graphic
methods. Descriptive or stratified analyses always preceded para-
metric modeling in order to confirm that the assumptions under-
lying the models were met. The results are reported as two-sided
P values with 95 percent confidence intervals. Analyses were per-
formed with the use of JMP software (version 3.1, SAS Institute,





We analyzed 47 newly diagnosed grade III or IV
gliomas (classified as anaplastic astrocytoma in 18 pa-
tients and as glioblastoma multiforme in 29). The
characteristics of the patients are shown in Table 1.




 promoter was found in
19 of the 47 tumors (40 percent) (Fig. 2), a frequen-










was not associated with the patient’s age, the Kar-
nofsky score for performance status, or the grade of
the tumor (P>0.3 for each comparison).
In univariate analyses, methylation of the promot-
er was positively correlated with the clinical response
and with overall and disease-free survival. Twelve of
the 19 patients with methylated tumors (63 percent)
had a partial or complete response to carmustine, as
compared with 1 of the 28 patients with unmeth-
ylated tumors (4 percent, P<0.001) (Table 2). The
lack of methylation was associated with a much high-
er risk of death (hazard ratio, 9.5; 95 percent confi-
dence interval, 3.0 to 42.7; P<0.001) (Fig. 3A). In
univariate analysis, no other factor had a statistically
significant relation with survival. The median time to
the progression of disease was 21 months for meth-
ylated gliomas and 8 months for unmethylated glio-
mas (P<0.001), and the hazard ratio associated with
nonmethylation was 10.8 (95 percent confidence in-























































































































 Promoter in Six Glioma Samples.
A methylation-specific PCR assay was used, with the SW48 cancer cell line as a positive control for
methylation, normal lymphocytes (NL) as a negative control for methylation, and water as a negative
PCR control. PBR322/Msp digest was used as the molecular-weight marker. U denotes the presence of
unmethylated genes, and M the presence of methylated genes. Three glioma samples (2, 4, and 6) show
methylation, and three samples (1, 3, and 5) are unmethylated.
1
U M U M U M U M U M U M U M U M U M
2 3 4 5 6 NL SW48 Water
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deaths among patients with gliomas containing a
methylated promoter (four deaths) made multivariate
analyses unreliable. The hazard ratio associated with a
nonmethylated glioma was either unchanged or in-
creased when other predictors were added individu-




The DNA-repair enzyme MGMT is a key factor in
resistance to alkylating agents, because the transfer of
alkyl groups to MGMT prevents the formation of le-




 It has been reported that
lack of MGMT in gliomas from patients who were
treated with chloroethylnitrosoureas had only a mod-
erate effect on overall survival, and the time to pro-










 gene, we found a much stronger influ-
ence of the presence or absence of the enzyme. The
accumulation of normal cells in the tumor, including
infiltrating lymphocytes, may complicate accurate as-
sessment of MGMT. The mixture of normal cells may
explain, in part, the difference between the biochem-





results of direct immunohistochemical examination of




 The use of methylation-spe-
cific PCR permits an assessment of methylation of the
MGMT promoter. Methylation status is an indicator
of the transcriptional activity of the gene in glioma
cells, and thus the presence or absence of the DNA-
repair enzyme.
In our study, methylation of the MGMT promoter
was associated with responsiveness to carmustine and
an increase in overall survival and the time to pro-
gression of disease. Moreover, the methylation status
of the promoter was more predictive of the outcome
of carmustine treatment than the grade of the tumor,
the Karnofsky performance status, or the patient’s age.
If further study confirms that methylation of the
MGMT promoter predicts responsiveness to carmus-
tine, the use of this alkylating agent might be reserved
for patients with gliomas in which the promoter is
methylated. Moreover, it might be possible to increase
the sensitivity of resistant tumors (those without meth-
ylation) with the use of agents that inhibit the MGMT
enzyme. One such inhibitor, O6-benzylguanine,17,18
is being investigated for this purpose. It is a substrate
for MGMT that inactivates the enzyme. O6-benzyl-
guanine has been shown to enhance the response to
alkyl nitrosoureas in vitro and in vivo.17,19 The use of
such an agent to increase the sensitivity of gliomas
to carmustine only in cases of resistant tumors might
prevent the toxic effects of the combination of these
drugs on normal tissues in patients who are already
sensitive to carmustine.
*CI denotes confidence interval.
TABLE 2. CLINICAL RESPONSE ACCORDING TO THE METHYLATION 






no. % (95% CI) no. % (95%CI)
Complete 0 0 (0–12) 2 11 (1–33)
Partial 1 4 (0–18) 10 53 (29–76)
No change 4 14 (4–33) 3 16 (3–38)
Progression of disease 23 82 (63–94) 4 21 (6–44)
Figure 3. Overall Survival (Panel A) and Time to the Progression
of Disease (Panel B) among Patients with Gliomas Treated with
Carmustine, According to the Methylation Status of the MGMT
Promoter.
Both overall survival and the time to the progression of disease
were significantly greater in the group of patients with methyl-
ation of the MGMT promoter than in the group without meth-
ylation. The association was independent of the type of tumor,
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